Darçın, T. Et Al. 2024. Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data. Hitit medical journal (Online) , vol.6, no.2 , 186-192.

Darçın, T., Serin, İ., Uğur, M. C., Ekinci, Ö., Hindilerden, İ. Y., Akpınar, S., ... Hacıbekiroğlu, T.(2024). Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data. Hitit medical journal (Online) , vol.6, no.2, 186-192.

Darçın, Tahir Et Al. "Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data," Hitit medical journal (Online) , vol.6, no.2, 186-192, 2024

Darçın, Tahir Et Al. "Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data." Hitit medical journal (Online) , vol.6, no.2, pp.186-192, 2024

Darçın, T. Et Al. (2024) . "Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data." Hitit medical journal (Online) , vol.6, no.2, pp.186-192.

@article{article, author={Tahir Darçın Et Al. }, title={Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data}, journal={Hitit medical journal (Online)}, year=2024, pages={186-192} }